scholarly journals Journal of Cardiology & Cardiovascular Therapy

2020 ◽  
Keyword(s):  
Cardiovascular Therapy

Galectins-A Potential Target for Cardiovascular Therapy

2017 ◽  
Vol 15 (4) ◽  
Author(s):  
Ghulam Md. Ashraf ◽  
Asma Perveen ◽  
Syed Kashif Zaidi ◽  
Ausaf Ahmad ◽  
Shazi Shakil ◽  
...  
Keyword(s):  
Potential Target ◽  
Cardiovascular Therapy

scholarly journals The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy

Polymers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 446 ◽  
Author(s):  
Francesco Nappi ◽  
Antonio Nenna ◽  
Domenico Larobina ◽  
Giorgia Martuscelli ◽  
Sanjeet Singh Avtaar Singh ◽  
...  
Keyword(s):  
Bare Metal Stents ◽  
Coronary Intervention ◽  
Myocardial Infarctions ◽  
Metal Stents ◽  
Long Term Effects ◽  
St Segment Elevation ◽  
Advantages And Disadvantages ◽  
Cardiovascular Therapy ◽  
St Segment ◽  
Drug Eluting

Coronary heart disease remains one of the leading causes of death in most countries. Healthcare improvements have seen a shift in the presentation of disease with a reducing number of ST-segment elevation myocardial infarctions (STEMIs), largely due to earlier reperfusion strategies such as percutaneous coronary intervention (PCI). Stents have revolutionized the care of these patients, but the long-term effects of these devices have been brought to the fore. The conceptual and technologic evolution of these devices from bare-metal stents led to the creation and wide application of drug-eluting stents; further research introduced the idea of polymer-based resorbable stents. We look at the evolution of stents and the multiple advantages and disadvantages offered by each of the different polymers used to make stents in order to identify what the stent of the future may consist of whilst highlighting properties that are beneficial to the patient alongside the role of the surgeon, the cardiologist, engineers, chemists, and biophysicists in creating the ideal stent.

Neurological complications of cardiovascular therapy

1987 ◽  
Vol 12 (3) ◽  
pp. 158-211 ◽  
Author(s):  
Albert C. Cuetter ◽  
Victor J. Ferrans
Keyword(s):  
Neurological Complications ◽  
Cardiovascular Therapy

Hepatocyte growth factor as potential cardiovascular therapy

2005 ◽  
Vol 3 (3) ◽  
pp. 513-519 ◽  
Author(s):  
Hironori Nakagami ◽  
Yasufumi Kaneda ◽  
Toshio Ogihara ◽  
Ryuichi Morishita
Keyword(s):  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Cardiovascular Therapy ◽  
Hepatocyte Growth

scholarly journals Clinical and therapeutic value of carotid intima-media thickness

2015 ◽  
Vol 76 (3) ◽  
Author(s):  
Enrico Vassallo ◽  
Francesca Musella ◽  
Susanna Mosca ◽  
Laura Casaretti ◽  
Roberto Formisano ◽  
...  
Keyword(s):  
Cardiovascular Events ◽  
Intima Media Thickness ◽  
Surrogate Endpoint ◽  
Carotid Intima Media Thickness ◽  
Risk Level ◽  
Media Thickness ◽  
Cardiovascular Therapy ◽  
Inter Observer Variability ◽  
The Status ◽  
Prevention Studies

Carotid Intima Media Thickness (IMT) has been widely used to predict cardiovascular events in primary and secondary prevention studies. Yet, the power of IMT to reclassify risk level on top of conventional risk assessment based on classical risk factors remains unsettled. In fact, recent data indicate that the prognostic power of IMT is lower than that provided by the identification of carotid plaques. The role of IMT as surrogate endpoint to assess the efficacy of cardiovascular protective therapies is also still debated. In fact, no studies have ever been designed and powered to show a relationship between changes in carotid IMT during follow-up and cardiovascular events. Recently, two metaanalysis of trials using IMT as surrogate endpoint failed to demonstrate an association between IMT regression and cardiovascular events. The reasons for the lack of predictive role for changes in IMT are uncertain. It has been shown that IMT is not a pure atherosclerotic index, being substantially affected by age and hemodynamic factors including blood pressure and vessel wall shear stress. In addition, the status of carotid vessels does not strictly reflect that of coronary arteries. Finally, intra and inter-observer variability of measurements may further limit the association between IMT changes in individual patients and cardiovascular risk. Thus, IMT represents a valuable risk marker in population studies but its role for tailoring cardiovascular therapy in clinical practice remains currently uncertain.

scholarly journals Cardiovascular therapy through nanotechnology – how far are we still from bedside?

2014 ◽  
Vol 6 (2) ◽  
Author(s):  
Iwona Cicha ◽  
Christoph D. Garlichs ◽  
Christoph Alexiou
Keyword(s):  
New Technologies ◽  
New Products ◽  
Cardiovascular Disorders ◽  
Safety And Efficacy ◽  
Characterization Methods ◽  
Tailored Treatment ◽  
Cardiovascular Therapy ◽  
Potential Applications ◽  
Multiple Challenges ◽  
Widespread Interest

AbstractRecent years brought about a widespread interest in the potential applications of nanotechnology for the diagnostics and the therapy of human diseases. With its promise of disease-targeted, patient-tailored treatment and reduced side effects, nanomedicine brings hope for millions of patients suffering of non-communicable diseases such as cancer or cardiovascular disorders. However, the emergence of the complex, multicomponent products based on new technologies poses multiple challenges to successful approval in clinical practice. Regulatory and development considerations, including properties of the components, reproducible manufacturing and appropriate characterization methods, as well as nanodrugs’ safety and efficacy are critical for rapid marketing of the new products. This review discusses the recent advances in cardiovascular applications of nanotechnologies and highlights the challenges that must be overcome in order to fill the gap existing between the promising bench trials and the successful bedside applications.

Sign in / Sign up

Export Citation Format

Share Document